The use of respiratory virus quantitation has been discussed primarily in relation to severity of individual patient illness and duration of viral shedding [10–12]. Clearly such quantitative values, whether GenMark nAMPs or TaqMan Ct values from commercial or lab developed assays, vary greatly from patient to patient and even within a patient depending primarily time of sample collection since days 1 and 2 of illness typically have the highest titers [12–14]. Other sources of quantitative difference result from variability in specimen type (e.g. nasopharyngeal vs BAL), variation in collection practices within the same specimen type, as well as patient variables such as immunosuppression, prior vaccination, age, etc. Although the semi-quantitative nAMP readings are not FDA approved for use in patient care, we looked at viral quantitation from the perspective of population seasonal averages, so that patient-related and pre-analytic variability should average out. Our data suggest that this is the case. Seasonal Influenza A population matrix gene nAMPs from the GenMark RVP assay were remarkably consistent between 3 different institutions in Florida for 3 Influenza seasons from 2012 to 2015. The slightly higher matrix gene nAMPs seen at UFHealth in 2012–2013 compared with 2014–2015 seems to be explained by a bi-modal distribution in the 2012–2013 season, suggesting there may have been a mixture of strains in circulation.